BACKGROUND: Thermal ablation is an effective treatment for patients with metastatic colon and rectal cancer and allows surgeons to offer curative intent therapy to patients who are otherwise not candidates for resection. We aimed to report outcomes of a single institution experience using microwave ablation (MWA) with or without resection to treat five or more liver metastases. METHODS: In this retrospective cohort study, the University of Minnesota Division of Surgical Oncology liver surgery database was queried to identify all patients who underwent thermal ablation of five or more colorectal liver metastases (CRLM) between 2012-2018. We reviewed patient, disease, and tumor characteristics and measured local, intrahepatic, and extrahepatic recurrence (EHR) rates. We also calculated median overall survival (OS) and disease-free survival (DFS). RESULTS: Ten patients identified had five or more (range, 5-18) tumors ablated with or without combined liver and bowel resection. Median age was 50, and most patients were male (70%) and Caucasian (90%). Four patients received ablation alone (5-12 lesions), while six had combined resection and ablation (5-18 lesions). Ablation was performed laparoscopically in six patients, and four had ablations without resection. All patients received pre- and post-operative chemotherapy. A median of 7 tumors were ablated per patient. Median follow-up was 2.3 years. Among 75 tumors ablated, ablation site recurrence (ASR) (within 1 cm of ablation site) was seen in three with a per-lesion recurrence rate of 4%. Intrahepatic recurrence (IHR) occurred in 6 (60%) patients and EHR in 1 (10%). Five patients underwent retreatment of IHR during follow-up. Median OS was 3 years and DFS was 7.1 months. At the time of last follow up, 6 patients were disease-free. CONCLUSIONS: Thermal ablation can provide acceptable DFS and OS, even with high volume metastatic colorectal cancers. Future efforts should be focused on defining selection criteria for those most likely to benefit from this aggressive approach. 2021 Journal of Gastrointestinal Oncology. All rights reserved.
BACKGROUND: Thermal ablation is an effective treatment for patients with metastatic colon and rectal cancer and allows surgeons to offer curative intent therapy to patients who are otherwise not candidates for resection. We aimed to report outcomes of a single institution experience using microwave ablation (MWA) with or without resection to treat five or more liver metastases. METHODS: In this retrospective cohort study, the University of Minnesota Division of Surgical Oncology liver surgery database was queried to identify all patients who underwent thermal ablation of five or more colorectal liver metastases (CRLM) between 2012-2018. We reviewed patient, disease, and tumor characteristics and measured local, intrahepatic, and extrahepatic recurrence (EHR) rates. We also calculated median overall survival (OS) and disease-free survival (DFS). RESULTS: Ten patients identified had five or more (range, 5-18) tumors ablated with or without combined liver and bowel resection. Median age was 50, and most patients were male (70%) and Caucasian (90%). Four patients received ablation alone (5-12 lesions), while six had combined resection and ablation (5-18 lesions). Ablation was performed laparoscopically in six patients, and four had ablations without resection. All patients received pre- and post-operative chemotherapy. A median of 7 tumors were ablated per patient. Median follow-up was 2.3 years. Among 75 tumors ablated, ablation site recurrence (ASR) (within 1 cm of ablation site) was seen in three with a per-lesion recurrence rate of 4%. Intrahepatic recurrence (IHR) occurred in 6 (60%) patients and EHR in 1 (10%). Five patients underwent retreatment of IHR during follow-up. Median OS was 3 years and DFS was 7.1 months. At the time of last follow up, 6 patients were disease-free. CONCLUSIONS: Thermal ablation can provide acceptable DFS and OS, even with high volume metastatic colorectal cancers. Future efforts should be focused on defining selection criteria for those most likely to benefit from this aggressive approach. 2021 Journal of Gastrointestinal Oncology. All rights reserved.
Authors: Marc Peeters; Timothy Jay Price; Andrés Cervantes; Alberto F Sobrero; Michel Ducreux; Yevhen Hotko; Thierry André; Emily Chan; Florian Lordick; Cornelis J A Punt; Andrew H Strickland; Gregory Wilson; Tudor-Eliade Ciuleanu; Laslo Roman; Eric Van Cutsem; Valentina Tzekova; Simon Collins; Kelly S Oliner; Alan Rong; Jennifer Gansert Journal: J Clin Oncol Date: 2010-10-04 Impact factor: 44.544
Authors: Rebecca L Siegel; Kimberly D Miller; Ann Goding Sauer; Stacey A Fedewa; Lynn F Butterly; Joseph C Anderson; Andrea Cercek; Robert A Smith; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2020-03-05 Impact factor: 508.702
Authors: Stefan Stättner; Florian Primavesi; Vincent S Yip; Robert P Jones; Dietmar Öfner; Hassan Z Malik; Stephen W Fenwick; Graeme J Poston Journal: Surg Today Date: 2014-03-16 Impact factor: 2.549
Authors: Kendall R McEachron; Jacob S Ankeny; Alexandria Robbins; Ariella M Altman; Schelomo Marmor; Donna D'Souza; Robben Schat; Benjamin Spilseth; Eric H Jensen Journal: Surg Oncol Date: 2020-11-30 Impact factor: 3.279
Authors: Charles S Fuchs; John Marshall; Edith Mitchell; Rafal Wierzbicki; Vinod Ganju; Mark Jeffery; Joseph Schulz; Donald Richards; Raoudha Soufi-Mahjoubi; Benjamin Wang; José Barrueco Journal: J Clin Oncol Date: 2007-10-20 Impact factor: 44.544
Authors: Camilo Correa-Gallego; Yuman Fong; Mithat Gonen; Michael I D'Angelica; Peter J Allen; Ronald P DeMatteo; William R Jarnagin; T Peter Kingham Journal: Ann Surg Oncol Date: 2014-06-03 Impact factor: 5.344
Authors: Luai R Zarour; Sudarshan Anand; Kevin G Billingsley; William H Bisson; Andrea Cercek; Michael F Clarke; Lisa M Coussens; Charles E Gast; Cristina B Geltzeiler; Lissi Hansen; Katherine A Kelley; Charles D Lopez; Shushan R Rana; Rebecca Ruhl; V Liana Tsikitis; Gina M Vaccaro; Melissa H Wong; Skye C Mayo Journal: Cell Mol Gastroenterol Hepatol Date: 2017-01-20
Authors: Theo Ruers; Frits Van Coevorden; Cornelis J A Punt; Jean-Pierre E N Pierie; Inne Borel-Rinkes; Jonathan A Ledermann; Graeme Poston; Wolf Bechstein; Marie-Ange Lentz; Murielle Mauer; Gunnar Folprecht; Eric Van Cutsem; Michel Ducreux; Bernard Nordlinger Journal: J Natl Cancer Inst Date: 2017-09-01 Impact factor: 11.816